Major
Established
描述
Carbamazepine dramatically reduces aripiprazole plasma levels through potent CYP3A4 induction, potentially rendering antipsychotic treatment ineffective.
机制
Carbamazepine induces CYP3A4, the primary enzyme metabolizing aripiprazole, reducing aripiprazole AUC by approximately 70%.
临床意义
Psychiatric relapse due to sub-therapeutic aripiprazole levels is a major risk; FDA labeling explicitly requires a dose doubling.
处理措施
Double aripiprazole dose when co-prescribed with carbamazepine per FDA label; monitor clinical response and reduce dose if carbamazepine is discontinued.